Spatial heterogeneity with specific mutations in the cancer-relevant genes, FGFR1, ALK and ATM, among others, was also detected in other patients in our cohort supporting that the spatial heterogeneity in druggable targets clearly presented in the case of patient CB1002 is likely not a rare exception, creating the need to re-evaluate targeted therapy decision-making. This evidence concerns the gene FGFR1 and cancer.